Latest Articles

Publication Date
Women's Musculoskeletal Health: Insights from the 2024 National Academies of Sciences, Engineering, and Medicine Report on Chronic Conditions.

In 2024, the National Academies of Sciences, Engineering, and Medicine (NASEM) published a report entitled Advancing Research on Chronic Conditions in Women. A major purpose of this report was to …

Published: June 18, 2026, midnight
Silent but Destructive: Ureteral Deep Infiltrating Endometriosis Progressing to Renal Injury - A Case Report.

Ureteral endometriosis is a rare form of deep infiltrating endometriosis that may lead to silent ureteral obstruction and progressive renal injury. Early diagnosis remains challenging because symptoms are often nonspecific.

Published: June 18, 2026, midnight
SA confirms nation-first media literacy program's rollout to all primary schools - psnews.com.au

SA confirms nation-first media literacy program's rollout to all primary schools psnews.com.au

Published: June 17, 2026, 9:23 p.m.
Sun Pharma to acquire Organon in US$11bn deal - FemTech World

Sun Pharma to acquire Organon in US$11bn deal FemTech World

Published: June 17, 2026, 10:47 a.m.
Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat - beQuoted

Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat beQuoted

Published: June 17, 2026, 9 a.m.
Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat - The Manila Times

Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat The Manila Times

Published: June 17, 2026, 8:29 a.m.
Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat - Yahoo Finance Singapore

Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat Yahoo Finance Singapore

Published: June 17, 2026, 8:05 a.m.
Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat - Dagens industri

Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat Dagens industri

Published: June 17, 2026, 7:01 a.m.
Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat - Cision News

Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat Cision News

Published: June 17, 2026, 7 a.m.
Association between urinary heavy metals, phthalates, phytoestrogens, and polycyclic aromatic hydrocarbons and endometriosis: A cross-sectional study from NHANES 1999 to 2016.

Research on the association between urinary heavy metals, phthalates, phytoestrogens (PEs), polycyclic aromatic hydrocarbons (PAHs), and endometriosis (EM) is limited. Data were from the National Health and Nutrition Examination Survey …

Published: June 17, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!